Option chain shows key data for Phio Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Phio Pharma.

Phio Pharma (NASDAQ:PHIO) Stock, Option Chain

Phio Pharma

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Crude Oil

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

NEOG

PHIO

SMPL

VERO

VINC

XXII

Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results

Nasdaq index

FMTO

SUNE

Nasdaq Gains Over 100 Points; Delta Air Lines Posts Upbeat Earnings

wall street christmas unsplash

AIFF

HEES

MBIO

NMHI

Dow Gains Over 200 Points; Signet Jewelers Shares Plunge

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corp

Press Releases

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

MetaVia

Polyrizon

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Phio Pharma

Phio Pharma (PHIO) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell